Back to Agenda
Advancing Chronic Disease Development: Insights from FDA, EMA, PMDA, CDE and other Global Regulators
Session Chair(s)
Jingyu (Julia) Luan, PHD
Executive Regulatory Science Director
AstraZeneca, United States
Chronic Disease Town Hall spotlights emerging programs and global initiatives for chronic disease drug development, outlines the current landscape, explores opportunities and challenges, and assesses strategies to boost efficiency and accelerate therapeutic innovation.
Learning Objective : Discuss the present landscape, opportunities, and challenges of chronic disease drug development; Describe emerging programs and global initiatives designed to facilitate development of chronic disease drugs; Assess various considerations and strategies to enhance the efficiency of chronic disease drug development.
Speaker(s)
Panelist
Ayaka Kubota, RPH
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Office of Safty II
Panelist
Representative Invited
FDA, United States
Panelist
Jeffrey Nahum Siegel, DrMed, MD
FDA, United States
Director, Office of Drug Evaluation Sciences, OND, CDER
Panelist
Representative Invited
European Medicines Agency, Netherlands
Panelist
Representative Invited
FDA, United States
Panelist
Maria Vassileva, PHD
DIA, United States
Chief Science and Regulatory Officer
Panelist
Representative Invited
National Medical Products Administration (NMPA), China
Have an account?